secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2026-08-05T10:33:07+00:00
Accession:  0001082554-26-000028
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics Reports Q2 2026 Revenue of $783.3M, Net Income Up 8% to $333M
--------------------------------------------------------------------------------

- Total revenues decreased 2% year-over-year to $783.3M; net income rose 8% to $333.0M.
- Tyvaso DPI revenues grew 4% to $326.6M; Nebulized Tyvaso fell 18% to $126.0M.
- Submitted NDAs for ralinepag tablets in PAH and Nebulized Tyvaso in IPF; potential approvals in 2027.
- Repurchased ~2.76M shares under $1.5B ASR agreements; $500M remaining in buyback program.
- R&D expense increased 9% to $146.3M driven by cardiopulmonary projects and contingent consideration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000108255426000028/0001082554-26-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000108255426000028/uthr-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001082554-26-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer